Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92)

Abstract

The authors thank Dr. Gloria Tridello for her assistance with the statistical analysis and Ms. Ilaria Zecchini for her assistance with data management.The following institutions and investigators participated in the current

Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B‐Cell Lymphoma treated with theAIEOP LNH‐97 protocol

“…The intent of the AIEOP LNH-97 protocol, i.e. to increase the cure rate while decreasing the treatment-related toxicity, was fully achieved, thus proving superiority compared to our previous LNH-92 trial (Pillon et al, 2004). The toxic death rate was reduced from 3Á5% to 1Á4%, with only 0Á4% of patients dying of toxicity during the initial phases of chemotherapy.…”

“…That study obtained final results [10-year overall survival (OS) of 89% and event-free survival (EFS) of 82%] comparable with contemporary international trials, but showed a high incidence of early toxicity and deaths (Pillon et al, 2004). The subsequent AIEOP LNH-97 protocol was developed aiming at reducing toxic deaths while improving EFS.…”

Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols

“…19,[31][32][33] Data on the additional impact of sex within the adolescent age group are lacking. Recently presented molecular data on somatic mutations in the variable region of rearranged immunoglobulin genes of 54 molecular Burkitt's lymphoma indicated two gene rearrangements occurring almost exclusively in pediatric patients o14 years of age, providing evidence for an antigen-driven selection, which might differ between pediatric and adult Burkitt's lymphoma cases.…”

Prophylactic First-Line Antibiotics Reduce Infectious Fever and Shorten Hospital Stay during Chemotherapy-Induced Agranulocytosis in Childhood Acute Myeloid Leukemia

“…The randomized, double-blind and multicenter prospective study conducted by Pillon et al [10] showed that the preventive use of amoxicillin/clavulanic acid in 173 pediatric patients with acute leukemia and lymphoma reduced neutropenic fever and infection by 12%. In particular, these patients did not receive any stimulating factors, but no significant difference was found between the prophylactic and control groups [18].…”

“…A prospective study conducted by the Nordic Society of Pediatric Hematology and Oncology (NOPHO) [10] reported that 10% of pediatric patients died mainly from infections after the 15th day of chemotherapy, and the NOPHO suggested the use of prophylactic antibiotic treatment and also emphasized the necessity of studying the benefits of combining the use of prophylactic antibiotics [11]. Various clinical studies and meta-analyses have demonstrated that preventive use of fluoroquinolone antibiotics effectively reduce bacterial infection rate, infectious fever and overall mortality rate [12,13,14].…”